Carregant...
Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer
Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospec...
Guardat en:
| Publicat a: | Curr Treat Options Oncol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7102206/ https://ncbi.nlm.nih.gov/pubmed/30101402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-018-0562-9 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|